Skip to main content

Weather alert

Due to Hurricane Isaias, our Patient Service Centers in affected areas may be closed. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational. For site-specific information, please use Find a location and enter your zip code.

Hide
Quest Diagnostics

Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer

Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer

Authors: Foulkes WD, Polak P

Citation: J Natl Cancer Inst. 2024 Aug 22:djae184. doi: 10.1093/jnci/djae184. Online ahead of print.

Specialties: Oncology, Genetics

Related content

Audio Podcast
Exploring Digital Pathology and Artificial Intelligence
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations
Conference Presentation
BRCA1 and BRCA2 Testing When a Familial Variant is Reported
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.